CLINICAL TRIALS PROFILE FOR TIVANTINIB
✉ Email this page to a colleague
Clinical Trials for Tivantinib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00777309 ↗ | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Completed | ArQule | Phase 2 | This is a randomized, placebo-controlled, double blind phase 2 study designed to compare treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small cell lung cancer. The study will enroll patients who have had one prior chemotherapy regimen (other than erlotinib) for NSCLC. |
| NCT00777309 ↗ | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Completed | ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) | Phase 2 | This is a randomized, placebo-controlled, double blind phase 2 study designed to compare treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small cell lung cancer. The study will enroll patients who have had one prior chemotherapy regimen (other than erlotinib) for NSCLC. |
| NCT00988741 ↗ | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | Completed | ArQule | Phase 2 | This is a global randomized, placebo-controlled, double-blinded Phase 2 study designed to compare treatment of ARQ 197 versus placebo in patients with unresectable HCC who had radiographic disease progression after systemic first line therapy or were unable to tolerate the therapy. |
| NCT00988741 ↗ | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | Completed | ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) | Phase 2 | This is a global randomized, placebo-controlled, double-blinded Phase 2 study designed to compare treatment of ARQ 197 versus placebo in patients with unresectable HCC who had radiographic disease progression after systemic first line therapy or were unable to tolerate the therapy. |
| NCT01055067 ↗ | ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors | Terminated | Daiichi Sankyo Inc. | Phase 2 | This is a multicenter, single-arm study for safety and efficacy. |
| NCT01055067 ↗ | ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors | Terminated | Daiichi Sankyo, Inc. | Phase 2 | This is a multicenter, single-arm study for safety and efficacy. |
| NCT01075048 ↗ | ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | Completed | Daiichi Sankyo Inc. | Phase 1/Phase 2 | ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the safety, tolerability, and efficacy of ARQ 197, define the recommended dose for Phase 2. After the recommended dose is determined for Phase 2, participants receive study drug or placebo with irinotecan and cetuximab. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Tivantinib
Condition Name
Clinical Trial Locations for Tivantinib
Trials by Country
Clinical Trial Progress for Tivantinib
Clinical Trial Phase
Clinical Trial Sponsors for Tivantinib
Sponsor Name
